dChan - Q Origins Project Archive

Top Insider equity Sale/Buy for week ending-July 20

Garmin is one of the world's leaders in designing, producing, and marketing satellite geopositioning systems (GPS). Net sales break down by family of products as follows:

marine and land geopositioning systems (94.9%): tracers and sensors, pocket assistants, automobile guidance systems, sporting equipment (equipped with detectors for speed, distance traveled, heart rate, etc.);
aerial geopositioning equipment (5.1%): high-frequency communication transmitters, aerial display products, digital transponders (for transmitting altitude and flight number, broadcast by towers and control radar systems), beacon receivers, audio panels, etc.

Products are marketed by nearly 4,000 independent distributors worldwide.

Net sales break down by area of activity between sports and fitness (25.6%), outdoor activities (24.2%), automotive (18.9%), aviation (18%) and marine (13.2%).

At the end of 2018, the group had 8 production sites located in the United States (4), Taiwan (3) and China.

Net sales break down geographically as follows: Americas (47.7%), Europe/Middle East/Africa (36%) and Asia/Pacific (16.3%).

Number of employees : 12 300 people.

https://www.marketscreener.com/GARMIN-LTD-4933/company/

https://www.secform4.com/insider-trading/1121788.htm

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company.

The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.

The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials.

The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein.

The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Number of employees : 33 people.

https://www.marketscreener.com/KALVISTA-PHARMACEUTICALS-32018912/company/

https://www.secform4.com/insider-trading/1348911.htm

Albert Cha, MD, PhD., has served as a member of KalVista’s Board of Directors since the consummation of the Carbylan Therapeutics, Inc. transaction in 2016. Dr. Cha served as a member of the Carbylan Board of Directors starting in November 2007.

In September 2000, Dr. Cha joined Vivo Capital, a healthcare investment firm, where he has served in various positions - most recently as a Managing Partner. Dr. Cha currently serves as a member of the Boards of Directors of Biohaven Pharmaceutical Holding Company Ltd.

(NYSE: BHVN), Ascendis Pharma A/S (NASDAQ: ASND) and several privately-held biotechnology and medical device companies. During the past five years, he also served as a member of the Boards of Directors of Aclaris Therapeutics, Inc. (NASDAQ: ACRS), Sierra Oncology, Inc.

(formerly ProNAi Therapeutics, Inc.) (NASDAQ: SRRA) and AirXpanders, Inc. (ASX: AXP). Dr. Cha received a BS and an MS from Stanford University and an MD and a PhD from the University of California, Los Angeles.

https://www.kalvista.com/about-kalvista/board-directors

Vivo Capital, LLC is a private equity and venture capital firm specializing in incubation, seed, startup, mezzanine, and PIPE investments in private and public companies. The firm seeks to invest in all financing stages from Series A to public companies.

It primarily invests in healthcare, biotechnology, and life science companies. The firm also seeks to invest in companies with later-stage therapeutic products in clinical development. It typically makes investments in United States and Asia Pacific based

companies with a focus on later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China.

Vivo Capital, LLC was founded in 1996 and is based in Palo Alto, California with additional offices in Beijing, China; Shanghai, China; and Taipei, Taiwan.

https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=19199